Limits...
Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients.

Kallergi G, Agelaki S, Papadaki MA, Nasias D, Matikas A, Mavroudis D, Georgoulias V - Breast Cancer Res. (2015)

Bottom Line: Trastuzumab reduced the percentage of patients with full-length HER2-positive CTCs from 70 % at baseline to 50 % (p = 0.035) after treatment while increased the percentage of patients with p95HER2-positive CTCs from 40 % to 63 %.Moreover, the overall survival of metastatic patients with p95HER2-positive CTCs was significantly decreased (p = 0.03). p95HER2-positive CTCs can be detected in both early and metastatic breast cancer patients.Their incidence is increased in the metastatic setting and their presence is associated with poor survival.

View Article: PubMed Central - PubMed

Affiliation: Laboratory of Τumor Cell Biology, School of Medicine, University of Crete, Voutes, 71110, Heraklion, Crete, Greece. kalergi@med.uoc.gr.

ABSTRACT

Introduction: The truncated form of human epidermal growth factor receptor 2 (p95HER2) lacks the HER2 extracellular domain and has been associated with poor prognosis and resistance to trastuzumab. In the present study, the expression of p95HER2 was investigated on circulating tumor cells (CTCs) from breast cancer patients.

Methods: Triple-staining immunofluorescent experiments were performed on peripheral blood mononuclear cells' (PBMCs) cytospins obtained from patients with early (n = 24) and metastatic (n = 37) breast cancer. Cells were stained with the pancytokeratin (A45-B/B3) antibody coupled with antibodies against the extracellular (ECD) and the intracellular (ICD) domains of HER2. Slides were analyzed with either confocal laser scanning microscopy or with the Ariol system.

Results: HER2-positive CTCs were identified in 55.6 % of early and 65.2 % of metastatic CTC-positive breast cancer patients. p95HER2-positive CTCs were identified in 11.1 % of early and 39.1 % of metastatic breast cancer patients (p = 0.047). In 14 patients with metastatic HER2-positive breast cancer, CTCs were also analyzed before and after first-line trastuzumab therapy. Trastuzumab reduced the percentage of patients with full-length HER2-positive CTCs from 70 % at baseline to 50 % (p = 0.035) after treatment while increased the percentage of patients with p95HER2-positive CTCs from 40 % to 63 %. Moreover, the overall survival of metastatic patients with p95HER2-positive CTCs was significantly decreased (p = 0.03).

Conclusions: p95HER2-positive CTCs can be detected in both early and metastatic breast cancer patients. Their incidence is increased in the metastatic setting and their presence is associated with poor survival. Longitudinal studies during anti-HER2 treatment are required to determine the clinical relevance of p95HER2-expressing CTCs.

No MeSH data available.


Related in: MedlinePlus

HER2 alterations on CTCs of metastatic breast cancer patients (n = 14) after trastuzumab administration. a Number of total CTCs per patient before and after trastuzumab-based chemotherapy. b Number of CK-positive/HER2-positive-expressing CTCs per patient before and after trastuzumab-based chemotherapy. c Number of p95HER2-expressing CTCs per patient before and after trastuzumab-based chemotherapy. d Number of CK-positive/HER2-negative-expressing CTCs per patient before and after trastuzumab-based chemotherapy.CK cytokeratin, CTCs circulating tumor cells, HER2 human epidermal growth factor receptor 2, p95HER2 the truncated form of HER2
© Copyright Policy - OpenAccess
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4541732&req=5

Fig4: HER2 alterations on CTCs of metastatic breast cancer patients (n = 14) after trastuzumab administration. a Number of total CTCs per patient before and after trastuzumab-based chemotherapy. b Number of CK-positive/HER2-positive-expressing CTCs per patient before and after trastuzumab-based chemotherapy. c Number of p95HER2-expressing CTCs per patient before and after trastuzumab-based chemotherapy. d Number of CK-positive/HER2-negative-expressing CTCs per patient before and after trastuzumab-based chemotherapy.CK cytokeratin, CTCs circulating tumor cells, HER2 human epidermal growth factor receptor 2, p95HER2 the truncated form of HER2

Mentions: Fourteen patients were screened for CK-positive cells before and after first-line trastuzumab-based chemotherapy. Ten of them had CK-positive cells before treatment; after treatment, the CTC numbers were reduced in six patients, remained unchanged in four and were increased in the remaining four patients (Fig. 4a).Fig. 4


Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients.

Kallergi G, Agelaki S, Papadaki MA, Nasias D, Matikas A, Mavroudis D, Georgoulias V - Breast Cancer Res. (2015)

HER2 alterations on CTCs of metastatic breast cancer patients (n = 14) after trastuzumab administration. a Number of total CTCs per patient before and after trastuzumab-based chemotherapy. b Number of CK-positive/HER2-positive-expressing CTCs per patient before and after trastuzumab-based chemotherapy. c Number of p95HER2-expressing CTCs per patient before and after trastuzumab-based chemotherapy. d Number of CK-positive/HER2-negative-expressing CTCs per patient before and after trastuzumab-based chemotherapy.CK cytokeratin, CTCs circulating tumor cells, HER2 human epidermal growth factor receptor 2, p95HER2 the truncated form of HER2
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4541732&req=5

Fig4: HER2 alterations on CTCs of metastatic breast cancer patients (n = 14) after trastuzumab administration. a Number of total CTCs per patient before and after trastuzumab-based chemotherapy. b Number of CK-positive/HER2-positive-expressing CTCs per patient before and after trastuzumab-based chemotherapy. c Number of p95HER2-expressing CTCs per patient before and after trastuzumab-based chemotherapy. d Number of CK-positive/HER2-negative-expressing CTCs per patient before and after trastuzumab-based chemotherapy.CK cytokeratin, CTCs circulating tumor cells, HER2 human epidermal growth factor receptor 2, p95HER2 the truncated form of HER2
Mentions: Fourteen patients were screened for CK-positive cells before and after first-line trastuzumab-based chemotherapy. Ten of them had CK-positive cells before treatment; after treatment, the CTC numbers were reduced in six patients, remained unchanged in four and were increased in the remaining four patients (Fig. 4a).Fig. 4

Bottom Line: Trastuzumab reduced the percentage of patients with full-length HER2-positive CTCs from 70 % at baseline to 50 % (p = 0.035) after treatment while increased the percentage of patients with p95HER2-positive CTCs from 40 % to 63 %.Moreover, the overall survival of metastatic patients with p95HER2-positive CTCs was significantly decreased (p = 0.03). p95HER2-positive CTCs can be detected in both early and metastatic breast cancer patients.Their incidence is increased in the metastatic setting and their presence is associated with poor survival.

View Article: PubMed Central - PubMed

Affiliation: Laboratory of Τumor Cell Biology, School of Medicine, University of Crete, Voutes, 71110, Heraklion, Crete, Greece. kalergi@med.uoc.gr.

ABSTRACT

Introduction: The truncated form of human epidermal growth factor receptor 2 (p95HER2) lacks the HER2 extracellular domain and has been associated with poor prognosis and resistance to trastuzumab. In the present study, the expression of p95HER2 was investigated on circulating tumor cells (CTCs) from breast cancer patients.

Methods: Triple-staining immunofluorescent experiments were performed on peripheral blood mononuclear cells' (PBMCs) cytospins obtained from patients with early (n = 24) and metastatic (n = 37) breast cancer. Cells were stained with the pancytokeratin (A45-B/B3) antibody coupled with antibodies against the extracellular (ECD) and the intracellular (ICD) domains of HER2. Slides were analyzed with either confocal laser scanning microscopy or with the Ariol system.

Results: HER2-positive CTCs were identified in 55.6 % of early and 65.2 % of metastatic CTC-positive breast cancer patients. p95HER2-positive CTCs were identified in 11.1 % of early and 39.1 % of metastatic breast cancer patients (p = 0.047). In 14 patients with metastatic HER2-positive breast cancer, CTCs were also analyzed before and after first-line trastuzumab therapy. Trastuzumab reduced the percentage of patients with full-length HER2-positive CTCs from 70 % at baseline to 50 % (p = 0.035) after treatment while increased the percentage of patients with p95HER2-positive CTCs from 40 % to 63 %. Moreover, the overall survival of metastatic patients with p95HER2-positive CTCs was significantly decreased (p = 0.03).

Conclusions: p95HER2-positive CTCs can be detected in both early and metastatic breast cancer patients. Their incidence is increased in the metastatic setting and their presence is associated with poor survival. Longitudinal studies during anti-HER2 treatment are required to determine the clinical relevance of p95HER2-expressing CTCs.

No MeSH data available.


Related in: MedlinePlus